ClinicalTrials.gg
RecruitingNCT06594536SulfoTDAHUpdated Nov 6, 2026

Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity

An interventional study of Sulforaphane and Placebo in Attention Deficit Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 6, 2026Now RecruitingFirst site in France+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Assistance Publique - Hôpitaux de Paris.

Started
2024
the only one that year
No phase
5 of 11
3 open now
Registered
6th of 11
by date

Among the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 5 with no phase, and was the 6th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

7 of the 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Attention Deficit Disorder with Hyperactivity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.

Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.

Read the detailed description

This is a randomised controlled trial with a double-blind control group. The aim is to test the efficacy of Sulforaphane versus placebo by comparing these two groups with a 1:1 ratio.

The primary objective is to evaluate the efficacy of sulforaphane treatment versus placebo on the total inattention and hyperactivity/impulsivity score measured by the ADHD-RS scale (parents) at 8 weeks in children aged 6 to 12 years suffering from ADHD.

The primary endpoint was the ADHD-RS parent inattention and hyperactivity/impulsivity score at 8 weeks.

Secondary objectives:

To assess the efficacy of sulforaphane treatment versus placebo at 2, 4 and 8 weeks in children aged 6-12 years with ADHD on:

  • Inattention and hyperactivity/impulsivity symptoms assessed by parents using the ADHD-RS;
  • Social interactions using the SRS scale (Social Responsiveness Scale);
  • Emotional dysregulation using the SDQ (Strength and Difficulties Questionnaire);
  • Global functioning using the CGI-S (Clinical Global Impression - Severity) and the CGI-I (Clinical Global Impression - Improvement).

To assess the effect of treatment with sulforaphane versus placebo on attention and inhibition at 4 and 8 weeks: using a specific neuropsychological assessment: CPT (Continuous Performance Test); symptoms of inattention and hyperactivity/impulsivity assessed by the teacher using the ADHD-RS self-questionnaire. Differences in behaviour may be observed depending on the context (school versus family). It is therefore important to have 2 sources of information for the ADHD-RS questionnaire: the parents and the teacher.

To assess the tolerability of treatment with sulforaphane from a clinical point of view (use of a PAERS (Paediatrician Adverse Events Rating Scale) and a biological point of view (blood count, AST, ALT, total and conjugated bilirubin, blood ionogram, urea, creatininemia, T4, TSH).

The subgroup of patients included in the Robert Debré Hospital will have a High Resolution Electroencephalogram (HR-EEG) in order to study the electroencephalographic markers of response to treatment with sulforaphane.

An interview to assess interest in and satisfaction with the treatment will be conducted with the parents (Robert Debré) and the child in the month following the end of the study as part of a qualitative study.

03

Conditions studied

  • Attention Deficit Disorder

Keywords

  • Sulforaphane
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 to 12
  • Diagnosis of ADHD according to criteria (Diagnostic and Statistical Manual of Mental Disorders)
  • Followed or hospitalised in an investigating centre
  • Consent of holders of parental authority
  • Patient covered by health insurance (social security or CMU)
  • Patients able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Allergy to broccoli
  • Psychotropic treatment including methylphenidate in the month prior to inclusion
  • Ongoing psychotherapeutic and/or psycho-educational treatment specific to ADHD
  • ASD (Autism Spectrum Disorder) according to criteria, intellectual disability (IQ\< 80)
  • Chronic neurological disease, epilepsy
  • Holders of parental authority under guardianship or curatorship
  • Previous intake of sulforaphane
  • Known hypothyroidism or current thyroid treatment
  • Participation in other interventional research involving the human person or being within the exclusion period following previous research involving the human person, where applicable
  • Patient under AME (state medical aid)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Sulforaphane

    Prostaphane® is a dietary supplement based on SULFODYNE®, a broccoli seed extract standardised in free, stabilised sulforaphane. Patients will receive treatment for 8 weeks at the following dosage: * 1 capsule/day up to 50 kg, * 2 capsules/day from 50.1 to 90 kg; * 3 capsules/day above 90 kg, Each capsule contains 10mg of Sulforaphane.

    Dietary Supplement: Sulforaphane

  • Placebo comparator
    Placebo

    Patients will receive treatment for 8 weeks at the following dosage: * 1 capsule/day up to 50 kg, * 2 capsules/day from 50.1 to 90 kg; * 3 capsules/day above 90 kg, Each capsule contains placebo.

    Other: Placebo

Interventions

  • Dietary supplementSulforaphane

    taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane

  • OtherPlacebo

    taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo

06

What researchers measure

Primary outcomes

  1. Inattention scores in ADHD-RS parents

    Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents

    Time frame: 8 weeks

  2. Hyperactivity/impulsivity scores in ADHD-RS parents

    Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents

    Time frame: 8 weeks

Secondary outcomes

  1. Inattention scores in ADHD-RS parents

    Inattention scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents

    Time frame: 2, 4 and 12 weeks

  2. Hyperactivity/impulsivity scores in ADHD-RS parents

    Hyperactivity/impulsivity scores in ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) parents

    Time frame: 2, 4 and 12 weeks

  3. Social Responsiveness Scale (SRS) scores and sub-scores

    Social Responsiveness Scale (SRS) scores and sub-scores

    Time frame: 4, 8 and 12 weeks

  4. Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score

    Strength and Difficulties Questionnaire (SDQ) emotional dysregulation sub-score

    Time frame: 2, 4, 8 and 12 weeks

  5. Sustained attention and inhibition scores in the CPT (Continuous Performance Test)

    Sustained attention and inhibition scores in the CPT (Continuous Performance Test)

    Time frame: 4 and 8 weeks

  6. CGI-S (Clinical Global Impression - Severity) score

    CGI-S (Clinical Global Impression - Severity) score

    Time frame: 4 and 8 weeks

  7. CGI-I (Clinical Global Impression - Improvement) score

    CGI-I (Clinical Global Impression - Improvement) score

    Time frame: 4 and 8 weeks

  8. ADHD-RS teacher inattention and hyperactivity/impulsivity scores

    ADHD-RS teacher inattention and hyperactivity/impulsivity scores

    Time frame: 4 and 8 weeks

  9. tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale)

    tolerance of treatment: Adverse events score: PAERS (Paediatrician Adverse Events Rating Scale)

    Time frame: 4 and 8 weeks

  10. tolerance of treatment: Blood sample: Blood count

    tolerance of treatment: Blood sample: Blood count

    Time frame: 8 weeks

  11. tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase)

    tolerance of treatment: Blood sample: ASAT (Aspartate aminotransferase)

    Time frame: 8 weeks

  12. tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase)

    tolerance of treatment: Blood sample: ALAT (Alanin aminotransferase)

    Time frame: 8 weeks

  13. tolerance of treatment: Blood sample: total bilirubin

    tolerance of treatment: Blood sample: total bilirubin

    Time frame: 8 weeks

  14. tolerance of treatment: Blood sample: conjugated bilirubin

    tolerance of treatment: Blood sample: conjugated bilirubin

    Time frame: 8 weeks

  15. tolerance of treatment: Blood sample: ionogram

    tolerance of treatment: Blood sample: ionogram

    Time frame: 8 weeks

  16. tolerance of treatment: Blood sample: urea

    tolerance of treatment: Blood sample: urea

    Time frame: 8 weeks

  17. tolerance of treatment: Blood sample: creatinine

    tolerance of treatment: Blood sample: creatinine

    Time frame: 8 weeks

  18. tolerance of treatment: Blood sample: T4

    tolerance of treatment: Blood sample: T4

    Time frame: 8 weeks

  19. tolerance of treatment: Blood sample: TSH

    tolerance of treatment: Blood sample: TSH

    Time frame: 8 weeks

  20. Robert Debré patients: EEG-HR (High Resolution Electroencephalogram)

    the criterion used will be the theta-beta ratio.

    Time frame: 4 and 8 weeks

  21. Robert Debré patients: qualitative study:

    The exploration criterion will be an in-depth description of the experience of the families and the child with regard to treatment with sulforaphane (interest and satisfaction).

    Time frame: one month post treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 32 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 32 months is above that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Aug 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 19, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Aug 1, 2027was Aug 2026
CompletionEst.
Sep 1, 2027was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
1 site added — first site in France
Show site
  • Robert Debre Hospital · Paris, France
Nov 6, 2026
Primary completion
Aug 1, 2026→Aug 1, 2027
Nov 6, 2026
Study completion
Sep 1, 2026→Sep 1, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • Robert Debre Hospital · Paris, France
    Primary completion Aug 1, 2026→Aug 1, 2027
    Study completion Sep 1, 2026→Sep 1, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06594536
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 1, 2024
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Eric ACQUAVIVA, PhD
Contact
eric.acquaviva@aphp.fr
0140034092 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulforaphane

Start the discussion